ABL-112

N/A

Report date: 2024/07/26 17:21:14

Base Information

Drug NameABL-112

Drug Alias NameABL112ABL-112

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionAnti-T cell immunoglobulin and ITIM domainsAnti-Tumor necrosis factor receptor superfamily member 9

TargetsT cell immunoglobulin and ITIM domainsTumor necrosis factor receptor superfamily member 9

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySouth Korea

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesAbl Bio Inc

China Registration ClassN/A

Develop Information

Active CompaniesAbl Bio Inc

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A